Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
J Med Chem. 2015 Feb 26;58(4):1644-68. doi: 10.1021/jm500672y. Epub 2015 Feb 4.
J Med Chem. 2015.
PMID: 25585174
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
Jebahi A, et al. Among authors: petigny lechartier c.
Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18.
Cancer Lett. 2014.
PMID: 24650799
Free article.
Item in Clipboard
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
Pétigny-Lechartier C, et al.
Mol Cancer Ther. 2017 Jan;16(1):102-115. doi: 10.1158/1535-7163.MCT-16-0342. Epub 2016 Dec 15.
Mol Cancer Ther. 2017.
PMID: 27980105
Item in Clipboard
Cite
Cite